Background: ErbB3 expression is associated with the constitutive phosphorylation of epidermal growth factor receptors in non-small cell lung cancer (NSCLC) cell line, calu3. ErbB3 post-translational levels have been reported by other investigators to be regulated by Neuregulin receptor dependent protein 1 (Nrdp1). Nrdp1, a ubiquitin ligase, down-regulates ErbB3 expression by directing it toward proteosomal degradation. Nrdp1 also down-regulates the expression of a large molecular weight survival protein, Bruce. The over-expression of ErbB3 in NSCLC then could result from loss of expression or lack of stabilization of Nrdp1. Depressed levels of Nrdp1 expression or function could then lead to activation of ErbB receptor mediated signaling pathways and to over-expression of Bruce thereby resulting in an inhibition of apoptotic pathways. This combination of events could lead to continuous, uncontrolled cell proliferation. It was our goal to investigate the role of Nrdp1 in ErbB receptor-mediated signal transduction and survival pathways of NSCLC cell lines. Methods: Lung cancer cell lines were purchased from ATCC and maintained as recommended. Cells are cultured in serum-free medium for 24-48 hours before incubation for 1-2 hours with inhibitors of EGFR, inhibitors of other signal transduction pathways, or DMSO solvent vehicle controls. EGF or medium is added to selected wells for the final 5 minutes of culture before preparation of cell lysates for Western blotting. Equal protein concentrations of the lysates are applied to wells of PAGE-gels, then submitted to electrophoretic separation by molecular weights in SDS-Tris-glycine buffer. Signal transduction pathways are investigated by probing Western blots with phospho-kinase sitespecific antibodies, anti-native protein antibodies and anti-actin as loading control. Results: The calu-3 line, of seven NSCLC lines examined, revealed a constitutive activation of EGFR as evidence by tyr845 phosphorylation in the absence of addition of exogenous ligand. The constitutive phosphorylation of Tyr845 was not inhibited by the specific EGFR tyrosine kinase inhibitor, AG1478. Tyr845 phosphorylation was inhibited, however with the src-kinase inhibitor PP2, suggesting that a src-family associated kinase may be responsible for activating EGFR. Immunoprecipitation studies revealed high ErbB3 expression with limiting levels of EGFR. ErbB2 was co-immunoprecipitated with ErbB3. Nrdp1 expression levels were decreased in the calu-3 cell line as compared with another NSCLC cell line, H1975. The effect of decreased Nrdp1 levels on expression of survival or anti-apoptotic molecules and on the expression of proteins that are associated with epithelial to mesenchymal transition (EMT) will be reported. Conclusions: Signaling pathways triggered through the EGFR family of receptors, ErbB1, B2, B3, and B4 play major roles in the development of epithelial tumors. Constitutive activation of EGFR and enhanced expression of ErbB3 resulted in decreased responsiveness to EGFR inhibition. Inhibition of the src-kinase pathway is a viable alternative to inhibit signals transduced through the ErbB triggered pathway in these cells, and should be considered for therapy of tumors with similar phenotypes. The mechanisms underlying enhanced expression of ErbB3 may be associated with Nrdp1 levels rather than a reflection of gene amplification. Nrdp1 levels were relatively low in the calu-3 cell line as compared with others. Nrdp1 expression and stabilization may contribute to maintaining active signal transduction and the transition of epithelial cancer cells to mesenchymal type, a phenotype more resistant to therapy. Background: A new class of cancer therapeutics targeting specific signaling pathways activated by genetic lesions (gene mutations, gene copy-number changes, structural genetic changes, etc.) has shown clinical success. However, the molecular heterogeneity of non-small cell lung cancer (NSCLC) challenges the successful clinical deployment of these agents. This is mostly due to the fact that only subsets of the tumors of a given subtype carry a specific genetic lesion (e.g., EGFR mutation). Such lesions cause dependency of the tumor cells on the activity of this oncogene and thus render the cells sensitive to agents targeting this oncogene or the downstream pathway. It is therefore desirable that the genetic lesions that lead to a particular oncogene dependency and thus, therapeutic vulnerability, be identified preclinical experiments prior to initiation of clinical trials. Likewise, taking such concepts into clinical testing requires real-time and accurate measurement of somatic (tumor-specific) genetic lesions in the tumor, irrespective of the quality of the tumor specimen. Methods and Results: In order to establish a pre-clinical mechanism that reflects the genetic diversity of primary NSCLC tumors and that enables systematic perturbation experiments using drug cancdidates, we collected 84 NSCLC cell lines. We have analyzed the somatic genetic lesions of these cell lines by determining gene copy numbers using 250.000K SNP arrays, gene expression levels using exon arrays and mutation status of known oncogenes and tumor suppressor genes. Using these data the NSCLC cell lines can be characterized according to the pattern of genetic lesions. We also show that the genetic profiles of this cell line panel reflect the somatic lesion landscape of primary NSCLC tumors. This model system can thus be used to identify the genetic pattern of those cell lines that are exquisitely sensitive to a specific therapeutic compound. Using this system we show that cell lines carrying lesions in the ERBB2 gene are highly sensitive to a dual-specificity EGFR/Her2 kinase inhibitor. Furthermore, modelling sensitivity and resistance to EGFR inhibitors in the cell line collection recapitulates clinical observations in that cell lines carrying amplified and mutated EGFR alleles were most sensitive to these inhibitors. These examples illustrate the power of an integrated functional genomics approach to provide a preclinical rationale for the deployment of targeted drugs in the clinic. Furthermore, we have established a sensitive parallel sequencing method, as well as a high-throughput oncogene mutation approach for genetic analysis of clinical cancer specimens. These approaches will help translating the insights gained from preclinical screening experiments into clinical practice. Conclusions: In summary, we apply large-scale functional genomics approaches to generate preclinical hypotheses for the deployment of targeted agents in the cancer clinic. Furthermore, we are working on
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